|
1.
|
Bast RC, Hennessy B and Lills GB: The
biology of ovarian cancer: new opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Yap TA, Carden CP and Kaye SB: Beyond
chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer.
9:167–181. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Menon U, Gentry-Maharaj A, Hallett R, et
al: Sensitivity and specificity of multimodal and ultrasound
screening for ovarian cancer, and stage distribution of detected
cancers: results of the prevalence screen of the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol.
10:327–340. 2009. View Article : Google Scholar
|
|
4.
|
Visintin I, Feng Z, Longton G, et al:
Diagnostic markers for early detection of ovarian cancer. Clin
Cancer Res. 14:1065–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yurkovetsky Z, Skates S, Lomakin A, et al:
Development of a multimarker assay for early detection of ovarian
cancer. J Clin Oncol. 28:2159–2166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kulasingam V, Pavlou MP and Diamandis EP:
Integrating highthroughput technologies in the quest for effective
biomarkers for ovarian cancer. Nat Rev Cancer. 10:371–378. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Paulsen T, Kjaerheim K, Kaern J, Tretli S
and Trope C: Improved short-term survival for advanced ovarian,
tubal, peritoneal cancer patients operated at teaching hospitals.
Int J Gynecol Cancer. 16:11–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Engelen MJ, Kos HE, Willemse PH, et al:
Surgery by consultant gynecologic oncologists improves survival in
patients with ovarian carcinoma. Cancer. 106:589–598. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Earle CC, Schrag D, Neville BA, et al:
Effect of surgeon speciality on processes of care and outcomes for
ovarian cancer patients. J Natl Cancer Inst. 98:172–180. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Fung ET: A recipe for proteomics
diagnostic test development: the OVA1 test, from biomarker
discovery to FDA clearance. Clin Chem. 56:327–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Moore RG, McMeekin DS, Brown AK, et al: A
novel multiple marker bioassay utilizing HE4 and CA125 for the
prediction of ovarian cancer in patients with a pelvic mass.
Gynecol Oncol. 112:40–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D and Burger RA: Phase III trial of carboplatin and
paclitaxel compared with cisplatin and paclitaxel in patients with
optimally resected stage III ovarian cancer: a Gynecologic Oncology
Group study. J Clin Oncol. 21:3183–3195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Dean M, Fojo T and Bates S: Tumor stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
14.
|
Szotek PP, Pieretti-Vanmarcke R,
Masakiatos PT, et al: Ovarian cancer side population defines cells
with stem cell-like characteristics and Mullarian inhibiting
substance responsiveness. Proc Natl Acad Sci USA. 103:11154–11159.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Alvero AB, Chen R, Fu H, et al: Molecular
phenotyping of human ovarian cancer stem cells unravel the
mechanisms for repair and chemo-resistance. Cell Cycle. 8:158–161.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Bapat SA, Mali AM, Koppikar CB and Kurrey
NK: Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer. Cancer Res.
65:3025–3029. 2005.PubMed/NCBI
|
|
17.
|
Zhang S, Balch C, Chan MW, et al:
Identification and characterization of ovarian cancer-initiating
cells from primary human tumors. Cancer Res. 68:4311–4320. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Baba T, Covery PA, Matsumura N, et al:
Epigenetic regulation of CD133 and tumorigenicity of
CD133+ ovarian cancer cells. Oncogene. 28:209–218. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Moserle L, Indraccolo S, Ghisi M, et al:
The side population of ovarian cancer cells is a primary target of
INF-α antitumor effects. Cancer Res. 68:5658–5668. 2008.PubMed/NCBI
|
|
20.
|
Hu L, McArthur C and Jaffe RB: Ovarian
cancer stem-like side-population cells are tumourigenic and
chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Leizer AL, Alvero AB, Fu HH, et al:
Regulation of inflammation by the NF-κB pathway in ovarian cancer
stem cells. Am J Reprod Immunol. Sept. 5–2010.(E-pub ahead of
print).
|
|
22.
|
Hall GD, Brown JM, Coleman RE, et al:
Maintenance treatment with interferon for advanced ovarian cancer:
results of the Northern and Yorkshire gynaecology group randomised
phase III study. Br J Cancer. 91:621–626. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Widschwendter M, Fiegl H, Egle D, et al:
Epigenetic stem cell signature in cancer. Nat Genet. 39:157–158.
2006. View
Article : Google Scholar
|
|
24.
|
Jones PA and Baylin SB: The epigenomic of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ito K, Bernardi R and Pandolfi PP: A novel
signalling network as a critical rheostat for the biology and
maintenance of the normal stem cell and the cancer initiating cell.
Curr Opin Genet Dev. 19:51–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Park JT, Chen X, Tropè CG, Davidson B,
Shih leM and Wang TL: Notch3 overexpression is related to the
recurrence of ovarian cancer and confers resistance to carboplatin.
Am J Pathol. 177:1087–1094. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Lis R, Touboul C, Mirshahi P, et al: Tumor
associated mesenchymal stem cells protects ovarian cancer cells
from hyperthermia through CXCL12. Int J Cancer. 128:715–725. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Rothenberg ML, Liu PY, Wilczynski S, et
al: Phase II trial of oral altretamine for consolidation of
clinical complete remission in women with stage III epithelial
ovarian cancer: A Southwest Oncology Group Trial (SWOG-9326).
Gynecol Oncol. 82:317–322. 2001. View Article : Google Scholar
|
|
29.
|
Bertelsen K, Jakobsen A, Stroyer I, et al:
A prospective randomized comparison of 6 and 12 courses of
cyclophosphamide, adriamycin, and cisplatin in advanced epithelial
ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Gynecol Oncol. 49:30–36. 1993. View Article : Google Scholar
|
|
30.
|
Lambert HE, Rustin GJ, Gregory WM and
Nelstrop AE: A randomized trial of five versus eight courses of
cisplatin or carboplatin in advanced epithelial ovarian carcinoma.
Ann Oncol. 8:327–333. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hakes TB, Chalas E, Hoskins WJ, et al:
Randomized prospective trial of 5 versus 10 cycles of
cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian
carcinoma. Gynecol Oncol. 45:284–289. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Barakat RR, Sabbatini P, Bhaskaran D, et
al: Intraperitoneal chemotherapy for ovarian carcinoma: results of
long-term follow-up. J Clin Oncol. 20:694–698. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Markman M, Liu PY, Wilczynski S, et al:
Phase III randomized trial of 12 versus 3 months of maintenance
paclitaxel in patients with advanced ovarian cancer after complete
response to platinum and paclitaxel-based chemotherapy: a Southwest
Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol.
21:2460–2465. 2003. View Article : Google Scholar
|
|
34.
|
Perez-Gracia JL and Carrasco EM: Tamoxifen
therapy for ovarian cancer in the adjuvant and advanced settings:
systematic review of the literature and implications for future
research. Gynecol Oncol. 84:201–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Berek J, Taylor P, McGuire W, Mary Smith
L, Schultes B and Nicodemus CF: Oregovomab maintenance
monoimmunotherapy does not improve outcomes in advanced ovarian
cancer. J Clin Oncol. 27:418–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Ozols RF: Maintenance therapy in advanced
ovarian cancer: progression-free survival and clinical benefit. J
Clin Oncol. 13:2451–2453. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Wong C, Wellman TL and Lounsbury KM: VEGF
and HIF-1α expression are increased in advanced stages of
epithelial ovarian cancer. Gynecol Oncol. 91:513–517. 2003.
|
|
38.
|
Yamamoto S, Konishi I, Mandai M, et al:
Expression of vascular endothelial growth factor (VEGF) in
epithelial ovarian neoplasms: correlation with clinicopathology and
patient survival, and analysis of serum VEGF levels. Br J Cancer.
76:1221–1227. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Brustamann H: Vascular endothelial growth
factor expression in serous ovarian carcinoma: relationship with
topoisomerase II alpha and prognosis. Gynecol Oncol. 95:16–22.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Kraft A, Weindel K, Ochs A, et al:
Vascular endothelial growth factor in the sera and effusion of
patients with malignant and non malignant disease. Cancer.
85:178–187. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Mesiana S, Ferrara N and Jaffe RB: Role of
vascular endothelial growth factor in ovarian cancer: inhibition of
ascite formation by immunoneutralization. Am J Pathol.
153:1249–1256. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Mabuchi S, Terai Y, Morishige K, et al:
Maintenance treatment with bevacizumab prolongs survival in an in
vivo ovarian cancer model. Clin Cancer Res. 14:7781–7789. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Burger RA, Sill MW, Monk BJ, Greer BE and
Sorosky JI: Phase II trial of bevacizumab in persistent or
recurrent epithelial ovarian cancer or primary peritoneal cancer: a
Gynecologic Oncology Group Study. J Clin Oncol. 25:5165–5171. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Cannistra SA, Matulonis UA, Penson RT, et
al: Phase II study of bevacizumab in patients with
platinum-resistant ovarian cancer or peritoneal serous cancer. J
Clin Oncol. 25:5180–5186. 2007. View Article : Google Scholar
|
|
45.
|
Richardson DL, Backes FJ, Seamon LG, et
al: Combination gemcitabine, platinum, and bevacizumab for the
treatment of recurrent ovarian cancer. Gynecol Oncol. 111:461–466.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Kaye SB: Bevacizumab for the treatment of
epithelial ovarian cancer: will this be its finest hour? J Clin
Oncol. 25:5150–5152. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Pàez-Ribes M, Allen E, Hudock J, et al:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009.PubMed/NCBI
|
|
48.
|
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Loges S, Mazzone M, Hohensinner P and
Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors:
angiogenesis revisited. Cancer Cell. 15:167–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Berchuck A, Rodriguez GC, Kamel A, et al:
Epidermal growth factor receptor expression in normal ovarian
epithelium and ovarian cancer. I. Correlation of receptor
expression with prognostic factors in patients with ovarian cancer.
Am J Obstet Gynecol. 164:669–674. 1991. View Article : Google Scholar
|
|
51.
|
Morishige K, Kurachi H, Amemiya K, et al:
Involvement of transforming growth factor alpha/epidermal growth
factor receptor autocrine growth mechanism in an ovarian cancer.
Cancer Res. 51:5951–5955. 1991.
|
|
52.
|
Bartlett JM, Langdon SP, Simpson BJ, et
al: The prognostic value of epidermal growth factor receptor mRNA
expression in primary ovarian cancer. Br J Cancer. 73:301–306.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Gordon AN, Finkler N, Edwards RP, et al:
Efficacy and safety of erlotinib HCl, an epidermal growth factor
receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with
advanced ovarian carcinoma: results from a phase II multicenter
study. Int J Gynecol Cancer. 15:785–792. 2005. View Article : Google Scholar
|
|
54.
|
Braly P, Nicodemus CF, Chu C, et al: The
immune adjuvant properties of front-line carboplatin-paclitaxel: a
randomized phase 2 study of alternative schedules of intravenous
oregovomab chemoimmunotherapy in advanced ovarian cancer. J
Immunother. 32:54–65. 2009. View Article : Google Scholar
|
|
55.
|
Jerne NK: Towards a network theory of the
immune system. Ann Immunol. 125C:373–389. 1974.PubMed/NCBI
|
|
56.
|
Wagner U, Köhler S, Reinartz S, et al:
Immunological consolidation of ovarian carcinoma recurrences with
monoclonal anti-idiotype antibody ACA125: immune responses and
survival in palliative treatment. Clin Cancer Res. 7:1154–1162.
2001.
|
|
57.
|
Reinartz S, Köhler S, Schlebusch H, et al:
Vaccination of patients with advanced ovarian carcinoma with the
anti-idiotype ACA125: immunological response and survival (phase
Ib/II). Clin Cancer Res. 10:1580–1587. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Pfisterer J, du Bois A, Sehouli J, et al:
The anti-idiotypic antibody abagovomab in patients with recurrent
ovarian cancer. A phase I trial of the AGO-OVAR Ann Oncol.
17:1568–1577. 2006.PubMed/NCBI
|
|
59.
|
Sabbatini P, Dupont J, Aghajanian C, et
al: Phase I study of abagovomab in patients with epithelial
ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer
Res. 12:5503–5510. 2006. View Article : Google Scholar : PubMed/NCBI
|
